Physician profile
Robert Bloom
NPI 1578512893
$12,591.47
in general payments reported to CMS, 2019-2025
36 companies · $3,370 in 2025
The $3,370 reported for 2025 was more than what 96% of Pediatric Ophthalmology and Strabismus Specialist providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $853 · 2021: $711 · 2022: $1,804 · 2023: $1,562 · 2024: $3,221 · 2025: $3,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,782 · Education: $198 · Entertainment: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,781.70 |
| Education | $197.98 |
| Entertainment | $172.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,524.73 | 2019-2025 | Clareon, Unity, Lensx |
| Amgen INC. | $1,307.49 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,009.20 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $959.85 | 2022-2025 | Infuse, Biotrue One Day, Stellaris |
| Horizon Therapeutics Plc | $669.71 | 2020-2023 | Tepezza |
| Abbvie INC. | $585.83 | 2022-2025 | Xen Glaucoma Treatment System, Alphagan P, Lumigan |
| Mallinckrodt Hospital Products INC. | $483.62 | 2024-2025 | Acthar |
| Biotissue Holdings INC. | $466.03 | 2022-2025 | |
| Sight Sciences, INC. | $374.38 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $366.45 | 2024-2025 | Tecnis Simplicity, Tecnis Iol, Catalys System |
| Glaukos Corporation | $325.80 | 2022-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Sandoz INC. | $314.15 | 2024-2025 | Cimerli |
| Regeneron Healthcare Solutions, INC. | $302.20 | 2022-2025 | Eylea Hd |
| Allergan, INC. | $288.69 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $285.68 | 2024-2025 | Purified Cortrophin Gel |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $222.63 | 2019 | |
| Aerie Pharmaceuticals, INC. | $215.57 | 2019-2021 | |
| Optos, INC. | $172.78 | 2023-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Microsurgical Technology, INC. | $152.49 | 2022 | |
| Rxsight INC | $151.59 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Astellas Pharma US INC | $143.46 | 2024 | Izervay |
| New World Medical,INC. | $140.03 | 2023-2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Oyster Point Pharma, INC. | $137.74 | 2023 | Tyrvaya |
| Harrow Eye, LLC | $137.63 | 2024 | Iheezo, Triesence |
| Ivantis, INC | $124.99 | 2021 | |
| Rayner Intraocular Lenses Limited | $123.67 | 2024 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Apellis Pharmaceuticals, INC. | $123.06 | 2023 | Syfovre |
| Shire North American Group INC | $115.43 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $108.42 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $51.43 | 2024 | |
| Carl Zeiss Meditec, INC. | $50.00 | 2020 | |
| Dompe US, INC. | $47.86 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $33.45 | 2022 | |
| Genentech USA, INC. | $25.60 | 2025 | Vabysmo |
| Alimera Sciences, INC. | $25.32 | 2024 | Yutiq, Iluvien |
| Thea Pharma INC. | $24.51 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.